In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Merck KGaA (0O14 – Research Report) today and set a price target of €168.00. The ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...

This integration builds trust in AI systems regarding data authenticity and origin,” said Thomas Endress, Head of M-Trust™, Merck KGaA, Darmstadt, Germany. “Our collaboration with Zebra ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

(RTTNews) - Zebra Technologies Corporation (ZBRA) and Merck KGaA have collaborated to tackle challenges in product verification, authenticity, and trust. The partnership will introduce M-Trust ...

Germany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s strategic tie-up with the China-based multinational tech ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...